Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galmed Pharmaceuticals Ltd. (GLMD : NSDQ)

• Company Description    Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $0.58 Daily Weekly Monthly 20 Day Moving Average: 137,228 shares Shares Outstanding: 5.48 (millions) Market Capitalization: $3.18 (millions) Beta: 0.62 52 Week High: $2.34 52 Week Low: $0.41 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.67% -10.28% 12 Week -10.75% -17.50% Year To Date -22.70% -28.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 16 ABBA HILLEL ROAD - RAMAT GAN,L3 5250608 ISR ph: 972-3693-8448 fax: 972-3693-8447 investor.relations@galmedpharma.com http://www.galmedpharma.com

• General Corporate Information    Officers Allen Baharaff - Chief Executive Officer and President Guy Nehemya - Chief Operating Officer and Data Protection Office Doron Cohen - Chief Financial Officer Yohai Stenzler - Chief Accounting Officer Shmuel Nir - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: M47238148 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/28/26 Share - Related Items Shares Outstanding: 5.48 Most Recent Split Date: 8.00 (0.08:1) Beta: 0.62 Market Capitalization: $3.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/28/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.20 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -178.79% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - -29.43 09/30/25 - -20.37 ROA 03/31/26 - - 12/31/25 - -26.00 09/30/25 - -18.16 Current Ratio 03/31/26 - - 12/31/25 - 6.55 09/30/25 - 7.98 Quick Ratio 03/31/26 - - 12/31/25 - 6.55 09/30/25 - 7.98 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - - 12/31/25 - 2.88 09/30/25 - 3.49 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©